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ABSTRACT
Background. Colon cancer patients are at risk for recur-
rence. Recurrent disease might be curable if detected early
by surveillance. However, data on the quality of surveil-
lance are scarce. The objective of this study is to analyze
the quality of surveillance after curative surgery for colon
cancer among a cohort of Swiss patients.
Patients and Methods. After curative surgery, 129 stage
I–III colon cancer patients were followed by chart review,
questionnaires, and phone interviews. National surveillance
guidelines mandate periodic measurement of carcinoem-
bryonic antigen (CEA) levels, abdominal ultrasound or
computed tomography (US/CT), and colonoscopy. How-
ever, surveillance was left to the discretion of the treating
physicians. Actual surveillance was compared with the
recommendations in the guidelines.
Results. Datasets of all 129 patients were available. Median
follow-up was 33.5 months (range 5.6–74.7 months).
Eighteen patients (14.0%) recurred during follow-up. Three-
year overall and disease-free survival were 94.7% and
83.5%, respectively. Periodic CEA measurements, US/CT,
and colonoscopies as recommended by the guidelines were
performed in 32.8%, 31.7%, and 23.8% of patients,
respectively. Forty-four patients (34.1%) received adjuvant
chemotherapy. For these patients there was a trend towards
better compliance with national surveillance guidelines than
for patients without adjuvant chemotherapy.
Conclusions. The quality of surveillance after curative
surgery for colon cancer among a cohort of Swiss patients
is inadequate. Further education of health care profes-
sionals and patients regarding the potential life-saving
benefits of surveillance is imperative. It is cardinal that
quality of surveillance is critically analyzed in other
countries with different health care systems as well.
Colon cancer is a common tumor in the Western world.
Despite new therapeutic regimens, mortality rates remain
considerable. In the USA, about 50,000 deaths from colon
cancer are anticipated annually.1,2 Patients can be cured if
the cancer is detected early and completely resected. How-
ever, up to 30–44% of colon cancer patients will develop
local recurrences and/or distant metastases even after cura-
tive surgery.3–5 In the majority of cases, the cancer will recur
within the first 2–3 years after resection of the primary
tumor.3,5,6 A high recurrence rate and the known early advent
of recurrences are the rational for surveillance after curative
surgery for colon cancer.3–5 There is compelling evidence
from three meta-analyses that patients benefit from intensive
surveillance after curative surgery for colon cancer and that
mortality can be significantly reduced by surveillance.7–9
Additional evidence from large-scale, adequately powered
trials that are currently underway is eagerly awaited.10,11
Surveillance aims to detect local tumor recurrence,
metastases, and metachronous colorectal cancer in an early
stage when treatment might still be curative.12–14 A pre-
requisite for meaningful surveillance is that the patient
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qualifies for potential surgical treatment of cancer recurrence
regarding age and comorbidities. Actual multimodal thera-
peutic regimens show good results for curative treatment of
colorectal cancer recurrence. Five-year survival rates of up
to 58% after curative resection of hepatic metastases can be
achieved.15–17 Moreover, modern neoadjuvant chemother-
apy regimens (e.g. FOLFOX or FOLFIRI) in addition with
biologic agents (e.g., bevacizumab, cetuximab) successfully
downstage resectable liver metastases; consequently, more
R0 resections and a 5-year survival rate of up to 50% can be
achieved.18,19 Therefore nihilism regarding treatment of
colorectal cancer recurrence is no longer justified, and sur-
veillance programs become increasingly important.
Surveillance programs have therefore been recom-
mended for colorectal cancer patients in several countries,
and appropriate surveillance guidelines have been issued
by various gastroenterological, oncological, and/or surgical
societies.12–14 The Swiss Society of Gastroenterology
(SGG), for example, regularly publishes the current Swiss
recommendations for surveillance after curative resection
for colorectal cancer. The SGG elaborated recommenda-
tions for the first time in 1996. Updated recommendations
followed in 1999, 2003, and 2007.12,20,21
Despite the tremendous importance of surveillance after
curative resection of colon cancer, there is very little data
on adherence to surveillance guidelines in the scientific
literature. Hence, the quality of surveillance after curative
surgery for colon cancer is largely unknown. Therefore, the
objective of this study was to analyze the quality of sur-
veillance after curative surgery for colon cancer among a
cohort of Swiss patients.
PATIENTS AND METHODS
Data presented in this study are based on follow-up of 165
patients with resected colon cancer who were enrolled into
the prospective ‘‘Swiss Multicenter Trial Sentinel Lymph
Node Procedure in Colon Cancer’’ (NCT 00826579)
between April 2000 and December 2005.22 The study was
conducted at three Swiss academic and university-affiliated
institutions in different geographic regions of Switzerland.
Follow-up of the patients was not part of the initial study
protocol. All treating physicians received a discharge letter
where surveillance according to national guidelines was
recommended to the treating physicians. However, actual
surveillance was left to the discretion of the respective
treating physicians: surveillance for patients not receiving
adjuvant chemotherapy was organized by their respective
general practitioners; surveillance for patients with adjuvant
chemotherapy was initiated by the medical oncologists, and
after completion of chemotherapy managed by general
practitioners.
Patients with primary metastatic disease [American Joint
Committee on Cancer (AJCC)23 stage IV; n = 18], patients
who deceased within 30 days after surgery (n = 6), patients
refusing surveillance (n = 1), and patients who did not
qualify for surveillance due to age and severe comorbidity
(n = 11) were excluded, leaving 129 eligible patients for
analysis.
All pertinent in- and outpatient files were retrospectively
reviewed, and the treating general practitioners, gast-
roenterologists, and patients received a questionnaire. In
addition, all patients still alive were contacted by phone at
the time of follow-up. We compared the actual surveil-
lance, which had been performed during follow-up, with
the national surveillance guidelines (Tables 1 and 2). As
the surveillance guidelines changed during the study per-
iod, the analysis of expected surveillance compared with
the actual surveillance was adjusted for the Swiss guide-
lines at the time of surveillance. Parameters analyzed were:
measurements of carcinoembryonic antigen (CEA); diag-
nostic imaging: ultrasound (US) or computed tomography
(CT); and colonoscopy. Although CT scans were not offi-
cially recommended until 2007, abdominal CT scan was
considered a valid substitute for ultrasound. Surveillance
according to Swiss guidelines was defined as an exami-
nation conducted within ±2 months for CEA and US/CT,
and within ±4 months for colonoscopy, respectively, from
the time point recommended in the guidelines. At each
time point, e.g., 6, 12, or 18 months postoperatively, the
percentages of patients receiving surveillance according to
the guidelines were calculated. The results are shown as the
median percentage and range of surveillance according to
the guidelines for each recommended examination. In case
TABLE 1 National surveillance guidelines for colon cancer 1999 as
published by the Swiss Society of Gastroenterology21
Months postoperatively 6 12 18 24 36 48 60
Ultrasound ? ? ?
Colonoscopy ?
Physical examination, CEA, CT scan No recommendation
TABLE 2 National surveillance guidelines for colon cancer 2003 as
published by the Swiss Society of Gastroenterology20
Months postoperatively 6 12 18 24 36 48 60
Physical examination ? ? ? ? ? ? ?
CEA measurement ? ? ? ? ? ? ?
Ultrasound ? ? ? ? ?
Colonoscopy ?
CT scan No recommendation
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of tumor recurrence, data were analyzed until palliative
situation was obvious, and scheduled surveillance accord-
ing to the guidelines was stopped. Additionally, we
compared the adherence to the Swiss surveillance guide-
lines between subgroups of patients who did or did not
receive adjuvant chemotherapy.
The study was approved by the ethical committees of
the participating centers, and was conducted in compliance
with the institutional guidelines for experimental investi-
gation with human subjects. All patients gave written
informed consent before being enrolled into the study.
Statistics
Categorical variables were statistically analyzed with
Fisher’s exact test, and survival data with the log-rank test.
Statistical analyses were performed using SPSS 13.0 for
Macintosh (SPSS Inc., Chicago, IL). A P-value \ 0.050




Datasets of all 129 eligible patients (75 male, 54 female)
were available. Median age was 72.7 years (range 27.3–
92.2 years), and median follow-up was 33.5 months (range
5.6–74.7 months). Initial tumor stages according to AJCC
were stage I (pT1/pT2 pN0 cM0) in 23 (17.8%), stage II
(pT3/pT4 pN0 cM0) in 59 (45.7%), and stage III (pTx pN1/
pN2 cM0) in 47 patients (36.4%).23 Forty-four (34.1%)
patients received adjuvant chemotherapy. Indications for
chemotherapy were stage III in 41 patients, locally
advanced primary tumor (pT4) in two node-negative
patients, and lymphatic vessel infiltration in one patient
(pT3 pN0 G3 L1). Eighteen patients (14.0%) recurred
during follow-up, five of whom (5/18, 27.8%) underwent
surgery again. Eleven patients (8.5%) died during follow-
up: six (4.6%) for tumor-related causes and five (3.9%) for
reasons unrelated to the colon cancer and without evidence
of recurrent disease. Three-year overall and disease-free
survival was 94.7% (stage I 91.3%, stage II 98.0%, and
stage III 92.3%; P = 0.727) and 83.5% (stage I 87.4%,
stage II 88.7%, and stage III 76.2%; P = 0.101), respec-
tively. Three-year overall survival for patients with and
without adjuvant chemotherapy was 95.1% and 94.5%,
respectively (P = 0.266). The corresponding three-year
disease-free survival rates were 80.3% and 85.3%,
respectively (P = 0.114). All in- and outpatient records on
laboratory results, imaging, and colonoscopy could be
obtained. Return rate of the questionnaires was 82.2%.
Carcinoembryonic Antigen
CEA in the context of surveillance had to be measured
in 125 of 129 patients during follow-up; four patients had
not reached the first time point for CEA measurement
6 months postoperatively. The median percentage of
patients with surveillance according to the guidelines by
CEA measurement was 32.8% (30.2–41.3%). Figure 1
shows a comparison of patients expected to undergo sur-
veillance by CEA measurement with patients with
surveillance according to the guidelines. In 20 of 125
patients (16.0%) not a single CEA measurement was per-
formed postoperatively.
Additionally, we compared adherence to the recom-
mended CEA measurements between subgroups of patients
who did or did not receive adjuvant chemotherapy. The
median percentage of surveillance according to the guide-
lines by CEA measurements was 43.6% (41.8–53.6%) and
26.8% (20.8–32.7%) for patients who did and who did not
receive chemotherapy, respectively (P = 0.064).
Ultrasound and CT Scan
US/CT in the context of surveillance had to be con-
ducted in 118 of 129 patients during follow-up; 11 patients
had not reached the first recommended time point for US/
CT. The median percentage of patients with surveillance
according to the guidelines by US/CT was 31.7% (30.6–
38.9%). Figure 2 shows a comparison of patients expected
to undergo surveillance by US/CT with patients with sur-

















FIG. 1 Surveillance by CEA measurement. The number of patients
expected to undergo surveillance based on Swiss guidelines is
compared with the number of patients for whom surveillance actually
was performed
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(29.7%) not a single ultrasound or CT scan was performed
postoperatively. The median percentage of surveillance
according to the guidelines by US/CT was 52.6% (41.6–
66.6%), and 21.4% (20.0–26.5%) for patients who did and
who did not receive chemotherapy, respectively
(P = 0.071).
Colonoscopy
A colonoscopy in the context of surveillance had to be
conducted in 21 of 129 patients during follow-up; the
remaining patients had not (yet) to be scheduled for sur-
veillance colonoscopy. However, only five patients (23.8%)
received a colonoscopy within the defined timeframe.
Moreover, preoperative colonoscopy was incomplete in 16
patients (12.4%), five of whom (5/16, 31.3%) never got a
completion colonoscopy postoperatively. Surveillance
according to the guidelines by colonoscopy was performed
in 40.0% (2 of 5 patients) and 18.8% (3 of 16 patients) for
patients who did and who did not receive chemotherapy,
respectively (P = 0.410).
Overall Surveillance
We also analyzed overall adherence to the surveillance
guidelines, i.e., whether all CEA measurements, US/CT,
and colonoscopies were performed according to the
guidelines. Only 15 of 129 patients (11.6%) underwent
complete surveillance as recommended by the guidelines.
On the other hand, 13.0% of patients did not have any of
the recommended examinations after curative colon cancer
resection.
DISCUSSION
We have analyzed the quality of surveillance after
curative surgery for colon cancer among a cohort of Swiss
patients. Adherence to national surveillance guidelines that
mandate periodic measurement of CEA levels, abdominal
US or CT scans, and colonoscopies was surprisingly poor.
Less than one-third of patients received surveillance
examinations according to the guidelines. Moreover, only
11.6% of patients underwent complete surveillance as
recommended by the Swiss guidelines, while 13.0% of
patient never had a single examination.
Data on the quality of surveillance after curative surgery
for colon cancer are generally scarce. To our knowledge,
this is the first investigation on adherence to a multiple-
item surveillance program, i.e., including more than peri-
odic surveillance colonoscopy. Other published studies
exclusively report adherence to surveillance colonoscopy
after surgery, as colonoscopy has been considered a key
component of surveillance.24–28 In a recent Dutch study,
Mulder and co-worker left the responsibility for organizing
the surveillance colonoscopy—as in our study—to the
general practitioners.24 Patients were not actively invited
for surveillance. Only 30% of eligible patients underwent
endoscopic surveillance within 1 year of the time point
recommended in the national guidelines; 52% of patients
had a delayed colonoscopy, and 18% had no colonoscopy
at all. The authors concluded that an active follow-up
invitation might be important.24 Data from the USA are
similar: Cooper et al. identified 5,716 patients older than
65 years after curative surgery for colorectal cancer in
1991 from the Medicare-Surveillance Epidemiology and
End Results database.25 Forty-nine percent of patients
never underwent a colonoscopy during the first 3 years
after surgery. Similarly, Elston Lafata and co-workers
reported that only about two-thirds of colorectal cancer
patients 30 years and older received the recommended
colon examination during the initial year after surgery.26
Our findings are in line with the Dutch study.24 However,
we did not only analyze the use of colonoscopies, but the
adherence to a multiple-item surveillance program, addi-
tionally including periodic CEA measurements and US/CT.
The unexpectedly high proportion of patients (13.0%) who
never had a single surveillance examination in our study is
very concerning. These patients were entirely excluded
from the potential life-saving benefits of surveillance.
In the present investigation, the treating physicians were
not questioned regarding why they did or did not adhere to
the surveillance guidelines. Therefore, we can only spec-
ulate on potential reasons for not performing some or all
surveillance examinations in the majority of patients. In
some health care systems, access to some of the recom-

















FIG. 2 Surveillance by ultrasound or CT scan. The number of
patients expected to undergo surveillance based on Swiss guidelines is
compared with the number of patients for whom surveillance actually
was performed
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developed health care system—comparable to the USA as
measured by the Organisation for Economic Co-operation
and Development (OECD) health data—and mandatory
health insurance coverage for all citizens grant access to
surveillance for each and every Swiss patient.29–31 Waiting
time for an ultrasound, a CT scan, or a colonoscopy is
usually only a few days, and insurance companies cover the
costs of all examinations recommended by the national
surveillance guidelines. Another explanation might be that
the treating physicians preferred one examination to
another. However, adherence to the respective surveillance
items (CEA, US/CT, and colonoscopy) consistently ranged
around 30%, indicating that this hypothesis is unlikely to
hold. Third, physician age, i.e., the time that has elapsed
since the doctor has trained, might explain differences in
adherence to the guidelines as well. As we did not record
physician age in this investigation, we cannot account for
this effect. However, Johnson et al. conducted a survey of
members of the Society of Surgical Oncology (SSO) and
the American Society of Colon and Rectal Surgeons (AS-
CRS) to address this issue.32 Surveillance practice patterns
did not vary substantially with practitioner age in this
study, and the authors concluded that continuous post-
graduate education is effective.32 Finally, it could be
hypothesized that treating physicians were not aware of the
need for surveillance per se and of the surveillance
guidelines in detail, even though the SGG recommenda-
tions were published in a journal that is sent to every
member of the Swiss Society of Physicians (FMH). This
hypothesis is supported by a study from Israel in which
general practitioners had to fill out a ten-item questionnaire
on the proper timing of colonoscopy for surveillance and
screening for colorectal cancer.33 The percentages of cor-
rect answer for the different items ranged from 6.2% to
58.5%. The authors concluded that physicians’ knowledge
on surveillance and screening guidelines for colorectal
cancer needed improvement.33
However, extensive knowledge on the details of the
surveillance guidelines is less important than the general
insight that surveillance after curative surgery for colon
cancer is important. We believe that this is the number one
reason why adherence to surveillance guidelines was so
poor in our investigation. This is somewhat surprising,
considering that all treating physicians in our study
received a discharge letter where surveillance according to
national guidelines was recommended for patients after
curative colon cancer resection.
It is well documented that practice patterns for surveil-
lance after curative surgery for colon or rectal cancer vary
substantially, e.g., depending on whether surveillance is
organized by a member of the SSO or the ASCRS.34,35
On the other hand, surveillance is not markedly intensified
for higher Tumor–Node–Metastasis (TNM) stages as
compared with early cancers.36 In our study, although far
from optimal, the quality of surveillance was found to be
considerably better in the subgroup of patients undergoing
adjuvant chemotherapy as compared with patients who did
not receive adjuvant treatment. It is possible that general
practitioners considered these patients to be at higher risk
for recurrence, and therefore performed surveillance
examinations more thoroughly. Additionally, medical on-
cologists closely followed these patients for several months
during the chemotherapy, and initiated surveillance.
Therefore, our data support strongly the statement in the
2007 SGG recommendations that surveillance is an inter-
disciplinary process that has to be coordinated by a single
person or institution.12
Additionally, it is critically important to convince health
care professionals and patients of the potential life-saving
benefits of surveillance. In this respect, educational efforts
on the professional level as well as for lays are mandatory.
As a first measure we have started to hand out a person-
alized surveillance schedule, including the dates when
surveillance examinations should be scheduled, directly to
our patients, giving them the opportunity to share the
responsibility for surveillance with their treating physi-
cians. However, as this change in practice pattern occurred
only after closure of this trial, we do not yet have data on
the effect of this measure. The creation of an (internet-
based) recall system, as suggested by Mulder et al., might
be another helpful tool.24
We would like to acknowledge the limitations of our
study: first, it is a retrospective investigation. However,
organizing and performing the surveillance examinations
was deliberately left to the discretion of the respective
treating physicians (general practitioners or medical on-
cologists). This study setting closely mimics the real
situation in Switzerland, where most patient care after
hospital discharge is performed by general practitioners. If,
in the context of a prospective trial, they had been aware of
the study objectives, they probably would have followed
the guidelines more closely. Therefore, our results give a
realistic view of surveillance performed after curative
surgery for colon cancer in Switzerland. The setting of this
trial (general practitioners referring their patients to an
academic or university-affiliated hospital) and the fact that
the patients were enrolled in a trial conceivably might have
biased our data; however, this possible bias would be, if
anything, in favor of better adherence to the surveillance
guidelines. Another limiting factor of our study is the fact
that the SGG guidelines were updated during the study
period.20 It is well conceivable that surveillance of patients
operated on before 2003 was not immediately adapted
when the new guidelines came into effect. Third, the poor
result could possibly be due in part to poor data capture, as
we cannot track insurance data by a national identification
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number in Switzerland. However, all patients still alive
were contacted by phone, and the return rate of the ques-
tionnaires was more than 80%. Finally, our definition of
surveillance according to the guidelines (±2 months for
CEA and US/CT or ±4 months for colonoscopy of
the recommended time point, respectively) might have
influenced the results. However, e.g., of 483 CEA mea-
surements, only 39 (8%) in 21 patients were performed
outside the defined time interval. We therefore conclude
that our results have only marginally (\10%) been affected
by our definition.
CONCLUSIONS
The quality of surveillance after curative surgery for
colon cancer is inadequate, even though access to sur-
veillance is granted for everybody by the Swiss health care
system. Further education of health professionals and
patients regarding the potential life-saving benefits of sur-
veillance is imperative. It is cardinal that quality of
surveillance is critically analyzed in other countries with
different health care systems as well.
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